Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. reports asset-sale, governance, clinical and regulatory, and corporate-status developments tied to its history as a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and serious infectious diseases. Its disclosed programs included arenavirus-platform cancer vaccine assets such as HB-200 (eseba-vec) and HB-700, as well as HB-400 for hepatitis B virus and HB-500 for HIV.
Company updates have covered completed sales of oncology, HBV, and HIV program assets, collaboration-related activity, board and stockholder matters, operating and financial results, and the voluntary delisting and deregistration process for HOOKIPA common stock.
HOOKIPA Pharma (NASDAQ: HOOK) announced the appointment of Professor Jean-Charles Soria to its Board of Directors. Recognized for his expertise in oncology and immunotherapy, Soria's addition is expected to enhance the scientific diversity of the board and support the company’s expansion of its clinical pipeline. Soria has extensive experience, including leadership roles at Gustave Roussy Cancer Center and AstraZeneca. HOOKIPA is focusing on developing immunotherapeutics targeting infectious diseases and cancers through its proprietary arenavirus platform.
Summary not available.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announces participation in the SVB Leerink’s CybeRx Series: Vaccine Forum on September 23-24, 2020. A fireside chat featuring CEO Joern Aldag and CMO Igor Matushansky will occur on September 23 at 12:00 PM ET. HOOKIPA focuses on developing immunotherapeutics for infectious diseases and cancers using their proprietary arenavirus platform. Their technologies include non-replicating and replicating platforms, with a Phase 2 trial ongoing for a Cytomegalovirus vaccine. They also collaborate with Gilead Sciences for HIV and Hepatitis B research.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has announced its participation in several virtual investor conferences in September 2020, featuring key presentations. The conferences include the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, where HOOKIPA will present on September 14 at 10:30 AM ET. Other notable events include the Morgan Stanley Virtual Global Healthcare Conference and the BofA Global Healthcare Conference. The company specializes in immunotherapeutics targeting infectious diseases and cancers, utilizing its proprietary arenavirus platform.
HOOKIPA Pharma reported its Q2 2020 financial results, highlighting a revenue increase to $6.7 million from $4.1 million year-over-year, mainly due to Gilead collaboration reimbursements. The company’s cash position stood at $93.3 million, down from $113.6 million at the end of 2019. R&D expenses decreased to $11.6 million, while G&A expenses rose slightly to $4.3 million. Net loss improved to $7.1 million compared to $12.1 million in Q2 2019. Notably, interim results for the Phase 2 trial of HB-101 showed positive safety and immunogenicity, with ongoing trials for HB-201 and HB-202 progressing well.
HOOKIPA Pharma (NASDAQ: HOOK) announced positive interim results from its Phase 2 clinical trial of the HB-101 CMV vaccine, aimed at kidney transplant patients. The trial, involving 51 CMV-negative individuals, showed that 84% experienced minimal adverse events, indicating good tolerability. Among participants receiving three doses, 100% mounted CMV-neutralizing antibodies. Furthermore, 100% of those receiving three doses exhibited a cellular immune response. The company plans to release preliminary efficacy data by the end of 2020.
HOOKIPA Pharma (NASDAQ: HOOK) announced the resignation of Dr. Sander van Deventer as a Non-Executive Director of its Board, effective immediately. He joined the Board in 2011 but will continue his role in the Scientific Advisory & Review Committee. The Board now consists of 8 members, with Dr. Jan van de Winkel as Chairman. HOOKIPA focuses on developing immunotherapeutics targeting infectious diseases and cancers, utilizing its proprietary arenavirus platform. Key projects include a Phase 2 CMV vaccine and collaborations with Gilead for HIV and Hepatitis B.
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, will present at the Jefferies Virtual Healthcare Conference from June 2-4, 2020. CEO will speak on June 3, 2020, at 8:30 a.m. ET. The presentation will focus on HOOKIPA's innovative immunotherapeutic platform targeting infectious diseases and cancers. Their proprietary technologies, VaxWave and TheraT, aim to enhance immune responses against diseases like CMV and HPV. The company is also collaborating with Gilead Sciences to develop treatments for HIV and hepatitis B.
Summary not available.
Summary not available.